MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, LBRX had $246,780K increase in cash & cash equivalents over the period. -$17,117K in free cash flow.

Cash Flow Overview

Change in Cash
$246,780K
Free Cash flow
-$17,117K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
Net loss
-13,733
Stock-based compensation expense
1,850
Shares issued for services rendered
0
Write off of deferred offering costs
0
Depreciation
236
Noncash lease expense
100
Realized gain on sale of marketable securities, net
119
(accretion) amortization of (discounts) premium on investments, net
-244
(gain) loss on change in fair value of derivative instruments
1,562
Prepaid expenses and other current assets
1,042
Operating lease liability
-36
Accrued interest on marketable securities
-168
Accounts payable and accrued expenses
-2,875
Net cash used in operating activities
-17,105
Purchases of property and equipment
12
Purchase of marketable securities
44,836
Proceeds from the sale of marketable securities
2,501
Maturities of marketable securities
2,500
Net cash (used in) provided by investing activities
-39,847
Proceeds from initial public offering
327,750
Payment of issuance costs for initial public offering
24,265
Proceeds from exercise of warrants and options
247
Proceeds from issuance of redeemable convertible series c preferred stock
0
Payment of issuance costs for redeemable convertible series c preferred stock
0
Net cash provided by financing activities
303,732
Net increase in cash, cash equivalents and restricted cash
246,780
Cash and cash equivalents at beginning of period
23,476
Cash and cash equivalents at end of period
270,256
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

LB PHARMACEUTICALS INC (LBRX)

LB PHARMACEUTICALS INC (LBRX)